Background: Lung cancer among female never-smokers constitutes a distinct clinicopathological entity with rising incidence. This study aims to characterize the epidemiological, histopathological, therapeutic, and outcome features of primary lung cancer in non-smoking women treated at CHU Hassan II, Fez. Methods: A retrospective review was conducted of medical records of female never-smokers diagnosed with primary lung cancer between insert study period. Variables analyzed included age, histology, stage (according to the 8th edition TNM), treatment modalities, EGFR mutation status, and clinical outcomes. Results: Mean age at diagnosis was 58 years (range: 28–82). Adenocarcinoma was predominant. At presentation, 62.9 % had metastatic disease, with brain involvement most common. Only 2.9 % had surgical resection; 22.9 % received curative chemoradiotherapy; 44.1 % received palliative radiotherapy. EGFR testing was conducted in 7 patients; 5 (71.4 %) were positive, and 3 received EGFR-targeted therapy. At median follow-up of 42 months: complete remission (2.9 %), partial remission (11.4 %), stable disease (17.1 %), progression (34.3 %), metastatic relapse (16 %), and 3-year mortality of 74.3 %. Conclusion: Adenocarcinoma predominance and high EGFR mutation frequency corroborate global trends in never-smoking women with lung cancer. These findings highlight the need for molecular diagnostics, tailored therapy, and public health interventions for this demographic.
Ayachi et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: